Mind the gap in kidney care : translating what we know into what we do
Copyright © 2024 World Kidney Day Steering Committee. Published by Elsevier Inc., on behalf of the International Society of Nephrology. Published by Elsevier Inc. All rights reserved..
Historically, it takes an average of 17 years to move new treatments from clinical evidence to daily practice. Given the highly effective treatments now available to prevent or delay kidney disease onset and progression, this is far too long. The time is now to narrow the gap between what we know and what we do. Clear guidelines exist for the prevention and management of common risk factors for kidney disease, such as hypertension and diabetes, but only a fraction of people with these conditions worldwide are diagnosed, and even fewer are treated to target. Similarly, the vast majority of people living with kidney disease are unaware of their condition, because in the early stages it is often silent. Even among patients who have been diagnosed, many do not receive appropriate treatment for kidney disease. Considering the serious consequences of kidney disease progression, kidney failure, or death, it is imperative that treatments are initiated early and appropriately. Opportunities to diagnose and treat kidney disease early must be maximized beginning at the primary care level. Many systematic barriers exist, ranging from patient to clinician to health systems to societal factors. To preserve and improve kidney health for everyone everywhere, each of these barriers must be acknowledged so that sustainable solutions are developed and implemented without further delay.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:105 |
|---|---|
| Enthalten in: |
Kidney international - 105(2024), 3 vom: 01. Feb., Seite 406-417 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Luyckx, Valerie A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chronic kidney disease |
|---|
| Anmerkungen: |
Date Completed 21.02.2024 Date Revised 21.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.kint.2023.12.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368656845 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368656845 | ||
| 003 | DE-627 | ||
| 005 | 20240222092128.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240220s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.kint.2023.12.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1301.xml |
| 035 | |a (DE-627)NLM368656845 | ||
| 035 | |a (NLM)38375622 | ||
| 035 | |a (PII)S0085-2538(23)00863-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Luyckx, Valerie A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mind the gap in kidney care |b translating what we know into what we do |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.02.2024 | ||
| 500 | |a Date Revised 21.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 World Kidney Day Steering Committee. Published by Elsevier Inc., on behalf of the International Society of Nephrology. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Historically, it takes an average of 17 years to move new treatments from clinical evidence to daily practice. Given the highly effective treatments now available to prevent or delay kidney disease onset and progression, this is far too long. The time is now to narrow the gap between what we know and what we do. Clear guidelines exist for the prevention and management of common risk factors for kidney disease, such as hypertension and diabetes, but only a fraction of people with these conditions worldwide are diagnosed, and even fewer are treated to target. Similarly, the vast majority of people living with kidney disease are unaware of their condition, because in the early stages it is often silent. Even among patients who have been diagnosed, many do not receive appropriate treatment for kidney disease. Considering the serious consequences of kidney disease progression, kidney failure, or death, it is imperative that treatments are initiated early and appropriately. Opportunities to diagnose and treat kidney disease early must be maximized beginning at the primary care level. Many systematic barriers exist, ranging from patient to clinician to health systems to societal factors. To preserve and improve kidney health for everyone everywhere, each of these barriers must be acknowledged so that sustainable solutions are developed and implemented without further delay | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a World Kidney Day | |
| 650 | 4 | |a chronic kidney disease | |
| 650 | 4 | |a equity | |
| 650 | 4 | |a kidney care | |
| 650 | 4 | |a public health | |
| 700 | 1 | |a Tuttle, Katherine R |e verfasserin |4 aut | |
| 700 | 1 | |a Abdellatif, Dina |e verfasserin |4 aut | |
| 700 | 1 | |a Correa-Rotter, Ricardo |e verfasserin |4 aut | |
| 700 | 1 | |a Fung, Winston W S |e verfasserin |4 aut | |
| 700 | 1 | |a Haris, Agnès |e verfasserin |4 aut | |
| 700 | 1 | |a Hsiao, Li-Li |e verfasserin |4 aut | |
| 700 | 1 | |a Khalife, Makram |e verfasserin |4 aut | |
| 700 | 1 | |a Kumaraswami, Latha A |e verfasserin |4 aut | |
| 700 | 1 | |a Loud, Fiona |e verfasserin |4 aut | |
| 700 | 1 | |a Raghavan, Vasundhara |e verfasserin |4 aut | |
| 700 | 1 | |a Roumeliotis, Stefanos |e verfasserin |4 aut | |
| 700 | 1 | |a Sierra, Marianella |e verfasserin |4 aut | |
| 700 | 1 | |a Ulasi, Ifeoma |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Bill |e verfasserin |4 aut | |
| 700 | 1 | |a Lui, Siu-Fai |e verfasserin |4 aut | |
| 700 | 1 | |a Liakopoulos, Vassilios |e verfasserin |4 aut | |
| 700 | 1 | |a Balducci, Alessandro |e verfasserin |4 aut | |
| 700 | 0 | |a World Kidney Day Joint Steering Committee |e verfasserin |4 aut | |
| 700 | 1 | |a Balducci, Alessandro |e investigator |4 oth | |
| 700 | 1 | |a Liakopoulos, Vassilios |e investigator |4 oth | |
| 700 | 1 | |a Hsiao, Li-Li |e investigator |4 oth | |
| 700 | 1 | |a Correa-Rotter, Ricardo |e investigator |4 oth | |
| 700 | 1 | |a Ulasi, Ifeoma |e investigator |4 oth | |
| 700 | 1 | |a Kumaraswami, Latha |e investigator |4 oth | |
| 700 | 1 | |a Lui, Siu Fai |e investigator |4 oth | |
| 700 | 1 | |a Abdellatif, Dina |e investigator |4 oth | |
| 700 | 1 | |a Haris, Ágnes |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Kidney international |d 1972 |g 105(2024), 3 vom: 01. Feb., Seite 406-417 |w (DE-627)NLM000007188 |x 1523-1755 |7 nnns |
| 773 | 1 | 8 | |g volume:105 |g year:2024 |g number:3 |g day:01 |g month:02 |g pages:406-417 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.kint.2023.12.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 105 |j 2024 |e 3 |b 01 |c 02 |h 406-417 | ||